Nasus Pharma Ltd. Form 6-K Summary
Business Context and Reporting Period
This Form 6-K filing covers the month of October 2025, with the report dated October 8, 2025. Nasus Pharma Ltd., a foreign private issuer based in Tel Aviv, Israel, reported a significant strategic development regarding its intranasal Epinephrine program (NS002). The filing details the execution of new agreements with AptarGroup, Inc. and its affiliate, Aptar France S.A.S., to advance the development and commercialization of this program.
Key Financial Metrics
The filing text does not provide specific financial statements, revenue figures, profit margins, cash flow data, debt levels, or liquidity metrics for the reporting period. The document focuses exclusively on the terms of a new commercial partnership rather than financial performance results.
Material Changes and Agreements
On October 6, 2025, Nasus Pharma entered into a series of agreements with AptarGroup, Inc. and Aptar France S.A.S., marking a material change in its operational strategy:
- Termination and Settlement: The Company terminated its 2019 Master Services Agreement (MSA) and related work schedules for Naloxone and Epinephrine with AptarGroup, Inc., resolving outstanding disputes.
- New Master Services Agreement (2025 MSA): A new MSA was signed with Aptar France S.A.S. to provide development, analytical, regulatory, and consulting services. This agreement is effective for five years or until service completion.
- Schedule of Work (2025 SOW): Aptar France will support the development and regulatory submission of the intranasal Epinephrine powder using the Unit Dose Powder (UDSp) device. Compensation includes staged fees over three years, milestone payments upon NDA submission and approval, and royalties on commercial sales for seven years.
- Supply Agreement: Aptar France will exclusively supply UDSp devices for the Epinephrine program, subject to FDA approval. Nasus Pharma committed to purchasing 100% of its requirements from Aptar France. The initial term is five years, renewable for two years.
Outlook, Risks, and Management Commentary
Management views this expanded collaboration as a critical step to support the development and commercialization of the NS002 Intranasal Epinephrine program. The agreements establish a long-term framework for regulatory submission and future supply chain needs. A primary contingency noted is that the Supply Agreement is subject to U.S. Food and Drug Administration (FDA) approval of the underlying program. The filing does not explicitly list other risks or unusual items beyond the resolution of prior disputes.
Key Facts for Investor Verification
- Confirmation that the 2019 disputes with AptarGroup have been fully settled and no further liabilities remain.
- Specific financial terms of the staged fees, milestone payments, and royalty rates under the 2025 SOW, which are not detailed in this filing.
- The timeline for the NDA submission and approval milestones that trigger payments to Aptar France.
- Current progress of the NS002 intranasal Epinephrine program toward FDA approval, which is a condition precedent for the Supply Agreement.
- Impact of the exclusive supply commitment on future manufacturing flexibility and cost structures.